1 / 11

Figure 1.

BMP6(206176_at). BMPR2(225144_at). ACVR2A(205327_at). Exprs 0 2 4 6 8 10 12. Exprs 0 2 4 6 8 10 12. Exprs 0 2 4 6 8 10 12.

steelemichelle
Download Presentation

Figure 1.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BMP6(206176_at) BMPR2(225144_at) ACVR2A(205327_at) Exprs 0 2 4 6 8 10 12 Exprs 0 2 4 6 8 10 12 Exprs 0 2 4 6 8 10 12 MBC PPC BMPC MM HMCL MBC PPC BMPC MM HMCL MBC PPC BMPC MM HMCL ACVR1(203935_at) ACVR2B(236126_at) BMPR1(213578_at) Exprs 0 2 4 6 8 10 12 Exprs 0 2 4 6 8 10 12 Exprs 0 2 4 6 8 10 12 MBC PPC BMPC MM HMCL MBC PPC BMPC MM HMCL MBC PPC BMPC MM HMCL Figure 1. A1 A2

  2. SMAD4(202527_at) SMAD1(210993_at) SMAD5(225219_at) Exprs 0 2 4 6 8 10 12 14 Exprs 0 2 4 6 8 10 12 14 Exprs 0 2 4 6 8 10 12 14 MBC PPC BMPC MM HMCL MBC PPC BMPC MM HMCL MBC PPC BMPC MM HMCL Figure 1. A3

  3. Figure 1. BMP6 BMP6 BMP6 BMP6 stimulation phosho-SMAD1,-5,-8 phosho-SMAD2 BMP6 Actin B1 B2 B3 XG-10 XG-11 U266 B4 C pMMC SKMM2

  4. Figure 2. + BMP6 Co + BMP6 + heparin U266 BMP6

  5. Figure 3. XG-1 XG-19 XG-11 U266 0.0 0.2 0.4 0.6 0.8 1.0 0.0 0.2 0.4 0.6 0.8 1.0 0.0 0.2 0.4 0.6 0.8 1.0 0.0 0.2 0.4 0.6 0.8 1.0 1.2 4 4 4 4 4 4 4 4 4 4 0 0 0 0 0 0 0 0 0 0 .00128 .00128 .00128 .00128 .00128 .00128 .00128 .00128 .00128 .00128 .8 .8 .8 .8 .8 .8 .8 .8 .8 .8 .0064 .0064 .0064 .0064 .0064 .0064 .0064 .0064 .0064 .0064 .032 .032 .032 .032 .032 .032 .032 .032 .032 .032 .16 .16 .16 .16 .16 .16 .16 .16 .16 .16 SKMM-2 OPM-2 LP-1 0.0 0.2 0.4 0.6 0.8 1.0 0.0 0.2 0.4 0.6 0.8 1.0 0.0 0.2 0.4 0.6 0.8 1.0 1.0 1.4 XG-13 XG-10 RPMI-8226 0.0 0. 0.4 0.6 0.8 1.0 1.2 0.0 0.2 0.4 0.6 0.8 1.0 0.0 0.2 0.4 0.6 0.8 1.0 1.2 A 3H-uptake BMP6-concentration (µg/ml)

  6. Figure 3. 6.6% 6.7 % 7.2 % 8.0 % 7.5 % 5.5 % 6.3 % 6.1 % 14.0 % 25.5 % 12.2 % 38.5 % 8.0 % 5.7 % 5.7 % 48 h 72 h 24 h 8 h B medium control medium control + heparin count BMP6 38.5 % BMP6 + heparin 7.1 % 8.0 % annexin V-FITC

  7. Figure 3. pMMC 2 pMMC 3 pMMC 1 * * * * * * Fraction of non-apoptotic MMC * * * * * * * BMP6-concentration (µg/ml) BMP6 stimulation Cleaved Caspase-8 Cleaved Caspase-9 Actin C D SKMM-2

  8. Figure 3. Noggin Noggin + 1 µg/ml BMP6 * 0.0 0.5 1.0 1.5 2.0 0.0 0.5 1.0 1.5 0 .032 .16 .8 4 20 0 BMP6 .032 .16 .8 4 20 Sclerostin Sclerostin + 1 µg/ml BMP6 * * * * 0.0 0.5 1.0 1.5 2.0 2.5 0.0 0.5 1.0 1.5 2.0 2.5 0 BMP6 .032 .16 .8 4 20 0 .032 .16 .8 4 20 E 3H-uptake Inhibitor-concentration (µg/ml)

  9. Figure 4. 0.1 0.2 0.3 0.4 0.5 0.6 tubule development positive negative 4 0.8 0.16 0.032 medium BMP6-concentration (µg/ml) A Medium control Positive control Negative control 0.16 µg/ml 0.032 µg/ml 0.8 µg/ml 4 µg/ml B

  10. Figure 5. OS HM-group BMP6high BMP6high BMP6high BMP6high P=.02 BMP6low BMP6low BMP6low BMP6low EFS LR-group EFS HM-group A OS LR-group P=.03 B

  11. Figure 5. EFS OS P=.03 WBM-BMP6high WBM-BMP6high WBM-BMP6low WBM-BMP6low C

More Related